NJ Senators Tell Congress 'Complicated Legal Framework' Hurts CBD Firms
NJ senators say although FDA deems dietary ingredients and food additives with CBD as unlawful, in the past three years more than 1,500 CBD products have come to market “without a clear approach for regulation or any plan from the FDA to balance consumer access and protect consumer health.”
You may also be interested in...
Responsible CBD supplement marketers are disadvantaged against bad actors with products taking up shelf space in “disloyal” retailers as federal regulatory limbo drags on, says nutritional science expert Duffy McKay. Patchwork of state regulations on CBD also create challenges.
Dietary supplement trade groups reacted on 26 November – in CRN’s case with umbrage – to the US Food and Drug Administration’s latest barrage of cannabidiol (CBD)-themed warning letters and accompanying update to consumers regarding CBD safety.
Congress should consider legislation authorizing agency to conduct enforcement more directly, says Associate Commissioner Schiller. In FDLI conference keynote, he discussed compliance with FDA regulations across markets it regulates, but made specific example of saying FDA is comparatively hamstrung in regulating businesses marketing products labeled as supplements.